Drug Combination Details
| General Information of the Combination (ID: C68636) | |||||
|---|---|---|---|---|---|
| Name | Silibinin NP Info | + | Methotrexate Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Rhabdomyosarcoma
[ICD-11: 2B55]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | Human rhabdomyosarcoma | Rhabdomyosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Silibinin improves the cytotoxicity of methotrexate in chemo resistant human rhabdomyosarcoma cell lines. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Silibinin improves the cytotoxicity of methotrexate in chemo resistant human rhabdomyosarcoma cell lines. Saudi Med J. 2013 Nov;34(11):1145-50. | |||
